Piper Sandler analyst Matt O’Brien notes the Centers for Medicare & Medicaid Services’ outpatient prospective payment system proposal this morning suggests overall rates to be up about 2.6% for calendar year 2025, though several codes rated higher in the ASC proposed rules include Sight Sciences (SGHT), Paragon 28 (FNA) and Inari Medical (NARI). On the negative side, CVRx (CVRX) is facing a potential reimbursement cut for Barostim procedures, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Announces the Release of its First Sustainability Report
- Sight Sciences publishes SAHARA RCT data demonstrating improved DED symptoms
- Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
- Sight Sciences announces publication of analysis from ROMEO study
- Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma